Inventor · disambiguated record
Randolf Kerschbaumer
Also filed as: KERSCHBAUMER RANDOLF · KERSCHBAUMER RANDOLF J
16 granted patents·17 pending applications·126 citations·filing 2000–2022
92Inventor score
Top patents by PatentIndex Score
33 records- 0195US7033590B1Factor IX/factor IXa activating antibodies and antibody derivativesBAXTER AG·Filed 2000·Granted Apr 25, 2006·47 cites·22 claims
- 0291US7501117B2Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLVBAXTER INNOVATIONS GMBH·Filed 2005·Granted Mar 10, 2009·12 cites·8 claims
- 0391US6926894B2Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLVBAXTER AG·Filed 2001·Granted Aug 9, 2005·39 cites·27 claims
- 0490US7279161B2Factor IX/factor IXa activating antibodies and antibody derivativesBAXTER AG·Filed 2005·Granted Oct 9, 2007·6 cites·9 claims
- 0581US7297336B2Factor IXa specific antibodies displaying factor VIIIa like activityBAXTER INT·Filed 2003·Granted Nov 20, 2007·6 cites·13 claims
- 0678US8668909B2Anti MIF antibodiesKERSCHBAUMER RANDOLF·Filed 2010·Granted Mar 11, 2014·5 cites·17 claims
- 0778US8399249B2Procedure for the generation of a high producer cell line for the expression of a recombinant anti-CD34 antibodyKERSCHBAUMER RANDOLF·Filed 2009·Granted Mar 19, 2013·8 cites·6 claims
- 0877US9465037B2Characterization of CHO-MIF gene and protein, and use thereofBaxalta GmbH·Filed 2012·Granted Oct 11, 2016·2 cites·29 claims
- 0976US7910094B2Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLVBAXTER INNOVATIONS GMBH·Filed 2009·Granted Mar 22, 2011·0 cites·6 claims
- 1070US8703426B2Composition exhibiting a von Willebrand Factor (vWF) protease activity with the amino acid sequence AAGGILHLELLVLAEMMLE BERNHARD·Filed 2008·Granted Apr 22, 2014·0 cites·9 claims
- 1166US2021187105A1Combination therapy of anti-mif antibodies and glucocorticoidsBAXALTA INC·Filed 2020·Application pending·0 cites
- 1265US9958456B2OxMIF as a diagnostic markerBaxalta GmbH·Filed 2012·Granted May 1, 2018·1 cites·11 claims
- 1365US8703429B2Composition exhibiting a von Willebrand Factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLVLAEMMLE BERNHARD·Filed 2008·Granted Apr 22, 2014·0 cites·6 claims
- 1464US9309506B2Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLVBAXALTA INC·Filed 2014·Granted Apr 12, 2016·0 cites·6 claims
- 1563US2017065686A1Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino Acid Sequence AAGGILHLELLVBAXALTA INC·Filed 2016·Application pending·0 cites
- 1661US2020207840A1Detection of cho-mif contaminationsBaxalta GmbH·Filed 2020·Application pending·0 cites
- 1757US2009220521A1Anti MIF AntibodiesKERSCHBAUMER RANDOLF·Filed 2008·Application pending·0 cites
- 1855US2017210794A1Characterization of cho-mif gene and protein, and use thereofBAXALTA INC·Filed 2016·Application pending·0 cites
- 1955US2015250873A1Combination therapy of anti-mif antibodies and glucocorticoidsBAXTER HEALTHCARE SA·Filed 2013·Application pending·0 cites
- 2054US2018280501A1Combination therapy of anti-mif antibodies and glucocorticoidsBAXALTA INC·Filed 2017·Application pending·0 cites
- 2153US2015023978A1Anti mif antibodiesBAXTER INT·Filed 2014·Application pending·0 cites
- 2252US10626166B2Detection of CHO-MIF contaminationsBaxalta GmbH·Filed 2015·Granted Apr 21, 2020·0 cites·12 claims
- 2351US2023365671A1IMPROVED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITYONCOONE RES & DEVELOPMENT GMBH·Filed 2021·Application pending·0 cites
- 2449US2013143238A1Procedure for the generation of a high producer cell line for the expression of a recombinant anti-cd34 antibodyBAXTER INT·Filed 2013·Application pending·0 cites
- 2546US2024307562A1ANTI-oxMIF RADIOIMMUNOCONJUGATEONCOONE RES & DEVELOPMENT GMBH·Filed 2022·Application pending·0 cites
- 2645US2015309012A1Anti-mif antibody cell migration assayBAXTER INT·Filed 2013·Application pending·0 cites
- 2744US2017049885A1Combination therapy of anti-mif antibodies and chemotherapeuticsBAXALTA INC·Filed 2016·Application pending·0 cites
- 2844US2023045873A1ANTI-oxMIF/ANTI-CD3 BISPECIFIC ANTIBODY CONSTRUCTSONCOONE RES & DEVELOPMENT GMBH·Filed 2020·Application pending·0 cites
- 2943US11402388B2Anti-MIF immunohistochemistryTAKEDA PHARMACEUTICALS CO·Filed 2013·Granted Aug 2, 2022·0 cites·15 claims
- 3043US2015071942A1Combination therapy of anti-mif antibodies and chemotherapeuticsBAXTER HEALTHCARE SA·Filed 2013·Application pending·0 cites
- 3139US2022002398A1ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENTONCOONE RES & DEVELOPMENT GMBH·Filed 2019·Application pending·0 cites
- 3235US2018155419A1Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant rasBaxalta GmbH·Filed 2016·Application pending·0 cites
- 3332US10613100B2Anti-MIF immunohistochemistryBAXALTA INC·Filed 2015·Granted Apr 7, 2020·0 cites·14 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →